International Society for Pharmacoeconomics and Outcomes Research

International Society for Pharmacoeconomics and Outcomes Research
Name	International Society for Pharmacoeconomics and Outcomes Research
Abbreviation	ISPOR
Formation	1995
Type	Professional association
Headquarters	Chicago, Illinois
Leader title	President

International Society for Pharmacoeconomics and Outcomes Research is a global professional association focused on health technology assessment and comparative effectiveness research. It brings together stakeholders from pharmaceutical industry, biotechnology industry, healthcare delivery systems and academic research to advance methods for cost–benefit analysis, quality-adjusted life year measurement and real-world evidence generation. The society operates through regional chapters, specialty groups and partnerships with regulatory and policy institutions.

History

The organization was founded in 1995 amid concurrent developments at Food and Drug Administration, National Institutes of Health, and World Health Organization that increased emphasis on outcomes research and pharmacoeconomics. Early leadership included figures affiliated with Harvard University, Johns Hopkins University, University of Oxford, and University of Toronto who sought to formalize methods used in publications in journals such as The Lancet, New England Journal of Medicine, and Health Affairs. Throughout the 2000s the society expanded alongside initiatives at European Medicines Agency, National Institute for Health and Care Excellence, Centers for Medicare & Medicaid Services and the Canadian Agency for Drugs and Technologies in Health, influencing guideline development and methodological standards.

Mission and Objectives

The society's stated mission aligns with priorities set by organizations such as World Health Organization, Organisation for Economic Co-operation and Development, and United Nations health programs: to improve decision making through evidence on value and outcomes. Core objectives include promoting methodological research exemplified by work from ISPOR Good Practices for Outcomes Research Task Force, setting standards akin to those of Cochrane, and fostering education comparable to programs at Johns Hopkins Bloomberg School of Public Health and University College London. The society emphasizes transparency similar to initiatives by International Committee of Medical Journal Editors and data sharing norms promoted by ClinicalTrials.gov.

Membership and Governance

Membership spans professionals from institutions such as Pfizer, Novartis, GlaxoSmithKline, Roche, Merck & Co., AstraZeneca, and Johnson & Johnson, as well as academics from Massachusetts Institute of Technology, Stanford University, Yale University, University of Cambridge, and Karolinska Institutet. Governance is overseen by an elected Board of Directors and committees with procedural resemblance to boards at American Medical Association and Royal Society. The society interacts with regulators including European Commission health directorates and advisory panels modeled on Advisory Committee on Immunization Practices. Membership categories mirror professional associations like American Heart Association and International Federation of Pharmaceutical Manufacturers & Associations.

Conferences and Publications

Annual and regional meetings follow formats similar to conferences hosted by American Society of Clinical Oncology, European Society of Cardiology, and American Public Health Association, featuring plenary sessions, workshops and poster sessions. Proceedings and consensus reports are published in journals such as Value in Health and sometimes inform technical reports at National Health Service agencies. The society has organized partnered meetings with International Society of Hypertension, Society for Medical Decision Making, and policy forums attended by representatives from European Parliament health committees and U.S. Congress advisory panels.

Research and Educational Activities

Research initiatives include methodological projects comparable to those conducted at Institute for Clinical and Economic Review and collaborative studies with academic centers including University of California, San Francisco, Imperial College London, and Monash University. Educational offerings encompass short courses, certification pathways and online modules resembling curricula at Coursera partners and professional development programs at Johns Hopkins University. Training targets professionals preparing submissions to agencies such as Health Technology Assessment International and to reimbursement bodies like Medicare and provincial authorities in Ontario.

Collaborations and Global Impact

Collaborations extend to multilateral organizations including World Bank, Pan American Health Organization, and national ministries of health in countries such as United Kingdom, Canada, Australia, Japan, and Brazil. The society's outputs have informed policy dialogues in settings from European Medicines Agency assessments to discussions at G20 health ministers meetings, and have been cited in technology assessments in Germany and France. Through partnerships with patient organizations, industry consortia and regulatory agencies, the society contributes to the global uptake of real-world data standards and international harmonization efforts spearheaded by groups like International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Health Technology Assessment International.

Category:Professional associations Category:Health economics organizations Category:Organizations established in 1995